API
< Back to all clusters
[HEALTH] · Mexico · 3 sources

started · updated

Cofepris authorizes weekly growth hormone treatment in Mexico

Mexico's Federal Commission for Protection against Sanitary Risks (Cofepris) has authorized the use of somapacitan for children aged 3 and older, as well as adolescents, suffering from growth retardation caused by growth hormone deficiency.

Unlike traditional daily administration treatments that require up to 365 applications per year, this new medication is administered weekly, reducing the frequency to 52 applications annually. According to Novo Nordisk, the international incidence of growth hormone deficiency is estimated between one in 3,000 and one in 10,000 live births, though specific national data for Mexico is currently unavailable.

Medical experts emphasize that monitoring growth curves rather than isolated height measurements is essential for detecting developmental disorders. Key indicators for evaluation include a drop in percentiles, a failure to grow at the expected rate, or unexplained short stature. Effective monitoring should consider growth velocity, family potential, nutrition, genetics, hormones, and chronic illnesses.

Entities

Angélica Licona · Cofepris · Mexico · Novo Nordisk